Antiplatelet therapy is associated with reduced mortality in patients with bloodstream infection: a propensity score-matched cohort study - PubMed
6 hours ago
- #Antiplatelet therapy
- #Bloodstream infection
- #Mortality reduction
- Antiplatelet therapy is associated with reduced 30-day all-cause mortality in patients with bloodstream infection (BSI).
- The study used propensity score matching to compare 248 patients (124 in each group) and found significantly lower mortality in the antiplatelet group (OR 0.35; 95% CI 0.17-0.71, P = 0.004).
- No significant differences were observed in secondary outcomes like septic shock, respiratory failure, acute kidney injury, or bleeding events between the groups.
- Subgroup analyses showed that antiplatelet therapy significantly reduced mortality in patients with Gram-negative BSI (OR 0.26; 95% CI 0.08-0.87; P = 0.029).
- Clopidogrel monotherapy was particularly effective, showing lower mortality (OR 0.17; 95% CI 0.03-0.90; P = 0.017).
- The study concludes that antiplatelet therapy reduces mortality in BSI patients without increasing bleeding risks.